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Abstract
Background: In Alzheimer’s disease, amyloid-β (Aβ) peptides aggregate in the lowering CSF amyloid levels - a key
pathological hallmark of the disease. However, lowered CSF amyloid levels may also be present in cognitively
unimpaired elderly individuals. Therefore, it is of great value to explain the variance in disease progression among
patients with Aβ pathology.
Methods: A cohort of n=2293 participants, of whom n=749 were Aβ positive, was selected from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database to study heterogeneity in disease progression for individuals with Aβ
pathology. The analysis used baseline clinical variables including demographics, genetic markers, and
neuropsychological data to predict how the cognitive ability and AD diagnosis of subjects progressed using statistical
models and machine learning. Due to the relatively low prevalence of Aβ pathology, models fit only to Aβ-positive
subjects were compared to models fit to an extended cohort including subjects without established Aβ pathology,
adjusting for covariate differences between the cohorts.
Results: Aβ pathology status was determined based on the Aβ42/Aβ40 ratio. The best predictive model of change in
cognitive test scores for Aβ-positive subjects at the 2-year follow-up achieved an R2 score of 0.388 while the best
model predicting adverse changes in diagnosis achieved a weighted F1 score of 0.791. Aβ-positive subjects declined
faster on average than those without Aβ pathology, but the specific level of CSF Aβ was not predictive of progression
rate. When predicting cognitive score change 4 years after baseline, the best model achieved an R2 score of 0.325 and
it was found that fitting models to the extended cohort improved performance. Moreover, using all clinical variables
outperformed the best model based only on a suite of cognitive test scores which achieved an R2 score of 0.228.
(Continued on next page)
*Correspondence: stempfle@chalmers.se
Data used in preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such,
the investigators within the ADNI contributed to the design and
implementation of ADNI and/or provided data but did not participate in
analysis or writing of this report. A complete listing of ADNI investigators can
be found at: London http://adni.loni.usc.edu/wp-content/uploads/
how_to_apply/ADNI_Acknowledgement_List.pdf
1Department of Computer Science and Engineering, Chalmers University of
Technology and University of Gothenburg, Gothenburg, SE
Full list of author information is available at the end of the article
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your
intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated in a credit line to the data.
Dansson et al. Alzheimer’s Research & Therapy          (2021) 13:151 Page 2 of 16
(Continued from previous page)
Conclusion: Our analysis shows that CSF levels of Aβ are not strong predictors of the rate of cognitive decline in
Aβ-positive subjects when adjusting for other variables. Baseline assessments of cognitive function accounts for the
majority of variance explained in the prediction of 2-year decline but is insufficient for achieving optimal results in
longer-term predictions. Predicting changes both in cognitive test scores and in diagnosis provides multiple
perspectives of the progression of potential AD subjects.
Keywords: Alzheimer’s disease, Amyloid-beta, Progression, Prediction, Machine learning
Background
About 50million people worldwide suffer from some form
of dementia, and 60–80% of all cases have Alzheimer’s
disease (AD) [1]. Patients who already suffer from mild
cognitive impairment (MCI) are at higher risk of devel-
oping AD [2, 3]. Studies have shown that the conversion
rate from MCI to AD is between 10 and 15% per year
with 80% of these MCI patients progressing to AD after
approximately 6 years of follow-up [4, 5]. Identifying those
who are at greatest risk of progression to AD is a central
problem.
A key pathological hallmark, required for an AD diag-
nosis, is the accumulation of Aβ peptides into plaques,
located extracellularly, and in intracellular tangles, con-
sisting of phosphorylated tau (p-tau) protein [6, 7]. The
precipitation of Aβ in the brain appears decades before
the patient shows symptoms during the so-called preclin-
ical stage of AD [8–10]. Lower levels of the aggregation-
prone peptide Aβ42 (or Aβ42/Aβ40 ratio) together with
increased levels of p-tau and total-tau (t-tau) are a core
cerebrospinal fluid (CSF) signature of AD [6]. However,
despite strong evidence for association between these
biomarkers and AD, individuals with significantly low-
ered Aβ ratio do not necessarily exhibit any cognitive
impairment [11, 12]. Therefore, Aβ pathology alone is not
sufficient as a predictor of disease progression [13, 14].
Although AD predictors and pathological hallmarks
have been researched for many years, today there is still
no drug available that cures AD or drastically changes its
course. New drug candidates that have potential disease-
modifying effects [15] are currently in development and
recently, the FDA approved Aduhelm for the treatment
of patients with AD under the Accelerated Approval pro-
cess. The FDA concluded that the benefits of Aduhelm for
patients with Alzheimer’s disease outweigh the risks of the
therapy.
If a successful treatment is developed, it is of utmost
importance that a prognostic tool is available to identify
the patients most likely to decline towards AD, to imple-
ment preventive treatments and interventions. This leaves
the challenge of predicting how patients with Aβ pathol-
ogy will progress, explaining the variation in cognitive
function of such subjects. As a result, a recent focus area
in applied statistical and computational research is pre-
dicting a change in diagnosis for patients progressing from
cognitively normal (CN) to MCI and from MCI to AD
[5, 16–19].
Most predictive models of neurodegenerative diseases
are based on recent advances in machine learning (ML)
models by obtaining data sets with measurements of cog-
nition and neuropathology from large cohorts [16, 20–22].
In this context, classificationmethods such as random for-
est [13, 21, 23, 24] and logistic regression (LR) [21, 25–27]
have been used to predict whether individuals will decline
or remain stable in their diagnosis.
Classification approaches are dependent on the avail-
ability of clinical labels and do not focus on capturing
patient-specific disease trajectories. To overcome this lim-
itation, disease progression has also been studied with
respect to continuous measures of the disease severity
[28, 29]. Previous works employed an elastic net linear
regression model [30, 31] to predict changes in cognitive
test scores to capture the patient’s cognitive ability over
time. The most common targets when predicting cogni-
tive decline are the Mini Mental Status Test (MMSE) [32]
and the Alzheimer’s Disease Assessment Scale-Cognitive
Subscale (ADAS-Cog) [33] scores [34–36].
In prediction modeling, the question arises as to which
of the considered input variables are particularly predic-
tive. In addition to predictors of AD diagnosis, relation-
ships between CSF biomarkers (CSF p-tau/Aβ42 ratio
and several other biomarkers) and prediction of cognitive
decline have been explored [26, 37–39]. However, even
though Aβ-positivity has been identified as a strong pre-
dictor of disease status, little is known about what deter-
mines the disease progression of Aβ-positive subjects
[27, 40].
This study aims to predict the future severity of demen-
tia for subjects with established presence of low Aβ levels
in CSF. We propose and demonstrate several predictive
models of disease progression for three different cohorts,
studying two primary aspects of progression: cognitive
decline and change in diagnosis. For the former, we pre-
dict the change in the MMSE cognitive test score both 2
and 4 years after baseline (the first visit of each patient).
For the latter, we use a classification approach to predict
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whether subjects will have a worse diagnosis 2 years after
baseline. Both tasks are addressed using linear and non-
linear prediction models, the parameters of which were
selected using ML methodology.
A predictive approach could be used to assist healthcare
professionals in evaluating and prioritizing patients for
treatment. Given that our model builds on only a small set
of biomarkers and demographic data, available for most
patients, the methodology is widely applicable.
Methods
Subjects and ADNI
The data used in this study were obtained from the
publicly available Alzheimer’s Disease Neuroimaging Ini-
tiative (ADNI) database (http://adni.loni.usc.edu). ADNI
collects clinical data, neuroimaging data, genetic data,
biological markers, and clinical and neuropsychological
assessments from participants at different sites in the USA
and Canada to study MCI and AD. Since its inception in
2003, several releases have been made; the cohorts used in
this work were assembled from ADNI 1,2,3 and GO.
The compiled data set used in this project includes 2293
subjects that were further filtered by eligibility criteria,
such as availability of diagnostic labels and on Aβ ratios.
Among the 2293 subjects, there were 749 Aβ-positive
subjects. The exclusion flowchart (see Fig. 2) describes
how many subjects are assigned to perform a prediction
task for the all subjects and Aβ-positive cohorts. For base-
line statistics of the processed Aβ cohort, see Table 1.
Tables 6 and 7 in the supplementary material show the
characteristics of all subjects and Aβ-positive subjects for
the three prediction tasks.
Determination of amyloid-positive status
The presence of Aβ plaques can be detected at a preclin-
ical stage years before the patient shows any symptoms
[9, 10]. While Aβ plaques (and tau-levels) may not be the
root cause of disease development [41], their abnormal
deposits in the brain uniquely define AD [6, 7]. However,
even among subjects with Aβ pathology, there is signifi-
cant variability in symptoms, such as cognitive function.
For this reason, our work is focused on predicting progres-
sion for subjects with lowered CSF levels of Aβ indicating
plaque formations in the brain. Subjects were evaluated
for Aβ pathology based on their Aβ42/Aβ40 ratio (here-
inafter simply Aβ ratio) as measured in CSF at baseline.
The full cohort was split into three groups: those who
had a baseline Aβ ratio lower than 0.13 (Aβ-positive),
those who had a higher ratio (Aβ-negative), and those
with unknown status. The threshold used in this work is
slightly higher than in some other works. For example, a
threshold of 0.0975 proposed in [42] for the diagnosis of
AD. However, as diagnosing ADwas not our primary con-
cern, we let the distribution of ratios themselves decide
the threshold, see Fig. 1, rather than tying it to a particular
prediction target.
Progression outcomes
We studied the progression of Aβ-positive subjects with
respect to two principal outcomes: change in cognitive
function relative to baseline and change in clinical demen-
tia diagnosis.
Cognitive function was assessed using the widely
adopted MMSE scale [32]. The MMSE score is com-
monly used as a target variable in clinical trials analyzing
Table 1 Baseline demographic and clinical characteristics of the ADNI cohort for Aβ-positive subjects and all subjects
Overall Aβ-positive Missing CN MCI AD All subjects All missing
n 749 132 411 206 2293
AGE, mean (SD) 73.7 (7.2) 1 75.2 (6.0) 73.2 (7.0) 73.6 (8.1) 73.2 (7.2) 9
Gender, n (%) m 415 (55.4) 0 55 (41.7) 247 (60.1) 113 (54.9) 1217 (53.2) 5
f 334 (44.6) 77 (58.3) 164 (39.9) 93 (45.1) 1071 (46.8)
MMSE, mean (SD) 26.5 (2.8) 0 29.0 (1.2) 27.4 (1.9) 23.3 (2.0) 27.4 (2.66 ) 5
ADAS13, mean (SD) 20.1 (9.6) 5 10.2 (4.6) 18.4 (6.7) 30.3 (7.7) 17.0 (9.25) 29
TAU, mean (SD) 337.1 (139.2) 7 281.5 (102.5) 334.3 (141.9) 378.6 (141.5) 285.6 (132.9) 1010
ABETA42, mean (SD) 754.0 (320.0) 0 885.3 (396.5) 761.5 (311.6) 654.8 (240.7) 1090.7 (607.5) 1014
FDG, mean (SD) 1.19 (0.15) 157 1.29 (0.11) 1.22 (0.14) 1.06 (0.13) 1.23 (0.15) 806
APOE4, n (%) 0 245 (34.5) 39 63 (50.4) 133 (34.5) 49 (24.6) 1162 (54.1) 147
1 345 (48.6) 56 (44.8) 187 (48.4) 102 (51.3) 780 (36.4)
2 120 (16.9) 6 (4.8) 66 (17.1) 48 (24.1) 204 (9.5)
Hippocampus, mean (SD) 6517.6 (1091.6) 168 7300.8 (788.8) 6585.0 (1029.8) 5883.8 (1008.4) 6794.0 (1185.7) 806
AV45, mean (SD) 1.37 (0.20) 312 1.29 (0.21) 1.36 (0.20) 1.44 (0.18) 1.21 (0.23) 1205
ABETARatio, mean (SD) 0.087 (0.029) 0 0.094 (0.020) 0.086 (0.023) 0.084 (0.023) 0.129 (0.057) 1014
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Fig. 1 Histogram showing the Aβ ratio of subjects at baseline. The different colored groups represent different diagnoses: dementia, MCI and CN.
The upper left histogram shows all diagnoses together and overlaps have blended colors like green and dark red
the treatment effects of drugs aimed at enhancing cogni-
tion for AD patients and in ML for predicting change in
patient’s cognitive ability [43, 44]. The MMSE comprises
a series of 20 individual tests covering 11 domains for a
total of 30 items. The test covers the person’s orientation
to time and place, recall ability, short-term memory, and
arithmetic ability. TheMMSE score takes values on a scale
from 0 to 30 where a lower score represents worse cogni-
tive function [45]. The specific targets of prediction were
the changes in MMSE score measured at follow-up visits
2 years after baseline and 4 years, relative to baseline.
Changes in dementia diagnoses were determined by
comparing the disease status (CN/MCI/AD) recorded in
ADNI at follow-up visits to the status at baseline. For
the corresponding prediction task, a binary variable was
created, indicating whether or not a subject’s diagnosis
had worsened in 2 years. Due to the low number of avail-
able subjects after 4 years, changes in diagnosis were
evaluated only 2 years after baseline. The models were
used to predict whether Aβ-positive subjects would trans-
fer from the CN group at baseline to either MCI or AD or
convert from MCI at baseline to AD at a follow-up visit
after 2 years.
Potential predictors
The covariates available at baseline (enrolment in ADNI)
contain analyzed biofluid samples from CSF, plasma,
and serum including different biochemical-markers such
as proteins, hormones, and lipids. Additionally, fea-
tures extracted from brain imaging biomarkers, such as
positron emission tomography (PET) scan and magnetic
resonance imaging (MRI) were included. Demographic
data such as age and gender were also considered.
The CSF samples include measurements of both Aβ42
and Aβ40, which are Aβ peptides ending at positions 42
and 40 respectively. Their ratio in CSF measurements has
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been proposed to better reflect brain amyloid production
than their individual measures [46, 47]. Therefore, the
ratio Aβ ratio in CSF is calculated and added as a new
feature for all subjects with both measurements available.
Predictive models were built on two different sets of
features. The first set of features (all features) was prese-
lected following [48] and expanded to include key features
from the ADNI TadPole competition [49] in addition to a
few features that were available for over 90% of the ADNI
cohort. This resulted in a set of 37 features including
biomarkers tau, p-tau, and Aβ42 in CSF, the PETmeasures
of AV45 and FDG, seven different size measurements of
brain regions, and 15 different cognitive tests. Moreover,
the FDG-PET data has beenmeasured by a research group
of UC Berkeley. The MPRAGEs (Magnetization Prepared
Rapid Acquisition Gradient Echo) for each subject is seg-
mented and parcellated with Freesurfer (version 5.3.0) to
define a variety of regions of interest in each subject’s
native space. The second feature set (cognitive tests only)
consists only of the 15 cognitive tests also present in the
all feature set. A full list and descriptions of the features
are given in Tables 1 and 2 in the supplementary mate-
rial. When building models for predicting the change in
MMSE score, the MMSE measures at baseline were not
included in the predictions since the target output itself
was calculated from the change in its baseline value.
Statistical analyses
We used machine learning methods to train predictive
models of cognitive decline within 2 (task A1) and 4 years
(task A2) from baseline, as well as a model for predicting
worsened diagnosis status (task B) after 2 years. The full
procedure, described further below, involved cohort sam-
ple splitting and weighting, model selection and fitting,
and evaluation.
Derivation and evaluation cohorts
Due to the small number of Aβ-positive subjects available
for each task (500/230/398 for tasks A1/A2/B, respec-
tively), see the exclusion flowchart in Fig. 2), we compared
training predictive models from only Aβ-positive subjects
to two ways of training using all subjects, irrespective of
Aβ status. All models were evaluated only on Aβ-positive
subjects, as they are the primary target of this work.
The first derivation setting (Aβ only) used only Aβ-
positive subjects for model derivation. This ensures that
model parameters are unbiased with respect to the Aβ-
positive cohort but may suffer from high variance due to
a small sample size. The second setting (all subjects) com-
bined Aβ-positive and Aβ-negative subjects and those
without Aβ measurements into one derivation set. Con-
sequently, the derivation sample size has been increased
substantially, at the cost of introducing bias into the sam-
ple, while the evaluation cohort remains the same.
In the third setting (all subjects, weighted), we applied
sample weighting to the all subjects cohort to mimic a
larger sample of Aβ-positive subjects. Each subject i was
assigned a weight wi > 0 based on the probability that
their individual Aβ-ratio ri would be observed for an aver-
age hypothetical Aβ-positive subject, as estimated using a
two-component Gaussian mixture model (GMM) [50] fit
to observed ratios.
We let the latent state C ∈ {0, 1} of a GMM, fit to
the Aβ-ratios of the all subjects cohort, represent Aβ-
positivity. The weight wi was computed as
wi = p̂(R = ri | C = 1)/p̂(R = ri) .
This is the ratio of the estimated probability to observe
the Aβ-ratio ri for an average Aβ-positive subject and
the overall probability of observing that ratio. This proce-
dure is described further in the supplementary material.
The weighting scheme assigns a higher weight to sub-
jects with Aβ-ratio more like that of Aβ-positive subjects
and lower to those with higher or unobserved ratios. The
weight was clamped between 0.2 and 1.0 so that sub-
jects with unmeasured or very high ratios were given
small but non-negligible influence and so that decidedly
Aβ-positive subjects would be given the weight 1.0. Each
prediction model was then fit to the weighted full sample
but evaluated only on held-out (unweighted) Aβ-positive
subjects.
Predictionmodels and learning objectives
First, we predicted the change in MMSE score relative
to baseline at the 2-year follow-up (task A1) and 4-year
follow-up (task A2) visits using two separate regressions.
Second, prediction of change in diagnosis after 2 years
(task B) was treated as a binary classification problem
(worse diagnosis/not worse diagnosis). For each task, we
considered both linear and non-linear estimators.
The first model type used for the MMSE prediction
was ordinary least squares linear regression. Similarly, for
the classification task, a logistic regression model was
used. The secondmodel type used both for regression and
classification was tree-based gradient boosting [51]. Gra-
dient boosting is an ensemble method where many weak
learners, in our case decision and regression trees, are
combined in an iterative fashion to create a strong one.
The trees are fit to the negative gradient of the loss func-
tion (mean squared error and logistic loss): iteratively, the
remaining residual error from the current tree model is
the target of the next model. The trained trees are then
combined together to form the final model. Our estimates
were made using the scikit-learn [52] library.
Model selection and evaluation
In this work, we are primarily interested in evaluating
how well machine learning models perform for previously
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Fig. 2 Exclusion flowchart showing the Aβ-positive (left) and all subjects (right) cohort. The graphs present the cohorts used for predicting the
change in MMSE (A1 and A2) and for the change in diagnosis after 2 years (B)
unseen subjects. To this end, sample splitting was used to
produce an unbiased estimate of the out-of-sample perfor-
mance of our models. We used k-fold cross-validation to
divide the Aβ-positive subjects into training and test sets.
Selection of hyperparameters for the gradient boosting
models then used a nested k-fold cross-validation scheme,
i.e., cross validation was further performed only on the
training samples to select hyperparameters from a grid
of possibilities to give a good trade-off between bias and
variance.
Cross-validation was used to divide the sample into k
outer folds of approximately the same size, k − 1 of which
were used for model derivation and 1 for validation. The
out-of-sample performance was measured by the average
across each combination of k derivation and validation
folds. In this work, 5-fold cross-validation (k = 5) was
used, training the model on 80% of the data and testing
it on the other 20%. This was repeated so that each sub-
set is used exactly once as a validation set and therefore
giving a better indication of how well the model performs
on unseen data. The overall performance can then be
estimated by averaging over the k folds [53].
Hyperparameter search was performed within each of
the k folds; each derivation set was further split again into
k inner folds k − 1 of which were used to select a set of
model hyperparameters and 1 fold used to validate these.
Once the best set was identified, according to the average
of the inner held-out folds, the model was retrained on
the entire outer derivation fold and tested on the held-out
data.
To get a robust and consistent evaluation, this proce-
dure was repeated 10 times for different fivefold cross-
validation splits and the average test score given as the
final performance, i.e., 50 held-out test score measures
from models with (possibly) different hyperparameters
are behind the average score and standard deviation
reported. As such, it is indicative of the average quality we
can expect from a model trained on a new similarly-sized
sample and evaluated on a held-out similarly sized sample.
The classification models were evaluated using the
weighted F1 score while the regression models used the
coefficient of determination—the R2 score—as a criterion.
The F1 score contained the weighted average of precision
and recall. Consequently, this score took both false posi-
tives and false negatives into account. The F1 was chosen
since it is usually more useful than accuracy, especially if
the data show an uneven class distribution [54]. The R2
measures how well the independent variables are capable
of explaining the variance of the dependent variable and is
defined by R2 = 1−Sres/Stot where Sres = ∑ni=1(yi − ŷi) is
the residual sum of squares and Stot = ∑ni=1(yi − y) is the
total sum of squares. An R2 value of 0 indicates that per-
formance is as good as predicting themean of the variable;
higher values are better. This definition of R2 takes values
in [−∞, 1] where negative values represent predictions
worse than the mean [55].
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Results
We first report the results of the data preprocessing steps,
present cohort statistics, and describe the imputation
approach of variables in the ADNI data set. Second, we
present the average rates of cognitive decline over time for
the CN, MCI, and AD groups, including both Aβ-positive
and Aβ-negative subjects. We then inspect the results for
models predicting change in MMSE relative to baseline
(A1, A2) and change in diagnosis (B). Finally, we study the
relationship between predictions in tasks A1 and B with
respect to the 2-year follow-ups.
Preprocessing
Preprocessing of the data started with zero-mean nor-
malization of continuous variables and one-hot encod-
ing (dichotomization) of categorical variables to reduce
variation in the variables’ scales. A simple imputation
scheme was used to address missingness in the covari-
ate set. For continuous features, missing values were
imputed using mean-imputation while categorical, one-
hot encoded features were zero-imputed. These pre-
processing steps are performed to maximize the size
of the available data and have all features on a simi-
lar scale. Since the available cohort for each task was
fairly small, and our focus was on held-out predic-
tion risk, which can be estimated in an unbiased way
irrespective of the imputation method, model-based
imputation was not used. Subjects with missing out-
comes were excluded from each corresponding prediction
task.
As our main focus is to study the progression of subjects
with Aβ pathology, we identified an Aβ-positive cohort by
examining the recorded ratio of Aβ40 andAβ42 at baseline.
To avoid introducing bias in the analysis, the ratio was not
imputed. For 1279 subjects, measurements of both Aβ40
and Aβ42 were available which resulted in an Aβ-positive
cohort of n = 749 subjects (see Fig. 2). It should be noted
that, over time, some participants left the study. Conse-
quently, different numbers of subjects were available at
follow-ups 2 and 4 years after baseline. The number of
Aβ-positive subjects with an MMSE test score available
2 years after baseline was 500 and 230 after 4 years. A
total of 398 subjects remained for the diagnosis change
prediction task.
The subgroup of Aβ-positive subjects had a mean age
of 73.7 years (std. of 7.2) over all the diagnosis groups.
The gender distribution over all groups was 55.4% male
and 44.6% female. The MMSE score was available for all
subjects at baseline: the CN group had a mean value of
29.0 (1.2), the MCI subgroup a mean of 27.4 (1.9), and AD
subjects 23.3 (2.0). Another important feature was the tau
variable, where measurements were available nearly for all
(99%) of the Aβ-positive subjects. Additionally, the main
genetic risk factor for AD, the APOE4 gene, of which a
person can have zero, one or two copies, was included
for almost all of the Aβ-positive cohort (only 39 were
missing) [56].
FDG, measured by positron emission tomography and
shown to be a strong marker for AD [47], was absent in
20.9% of the cohort. The statistics of key features used in
the three prediction tasks are presented in Table 1 for the
subgroup of Aβ-positive subjects and in Table 6 in the
supplementary file for the cohort of all subjects.
Average rates of cognitive decline
For each visit at t = 1/2, 1, 2 and 4 years after baseline,
the average MMSE score was calculated for observations
of different groups divided based on baseline diagnosis
(CN, MCI, AD) and Aβ-cohorts (Aβ-positives and Aβ-
negatives). The results are shown in Fig. 3. While we
observe a noticeable difference in the rate of cognitive
decline between the Aβ-positive and negative groups for
the MCI subjects, the two CN groups differ only slightly
in their trajectories. For the group of AD-positive partici-
pants, the meanMMSE score increases again after 2 years.
However, it is likely that this change is due to the dropout
of a significant number of study participants around this
time, resulting in a cohort with different characteristics
than at baseline.
The average MMSE score for the Aβ-positive MCI
groupwas 23.79 4 years after the baseline visit, while it was
initially 27.40—a decrease on average by 3.61. In contrast,
the average score of the MCI Aβ-negative group started
at 28.27 and averaging 28.20 score points after 4 years,
showing an average decrease of only 0.07. The analy-
sis shows for the CN Aβ-positive and negative groups a
decrease in the average score of 0.70 and an increase of
0.08 respectively.
As expected, Aβ-positivity was strongly correlated with
faster progression. Although there were remarkable dif-
ferences in the average deterioration of the MMSE score
between the Aβ groups, it should be noted that there
was a significant number of missing observations for each
group and time point after the baseline visit, due to sub-
jects not undergoing a certain inspection or dropping out
of the study. For reference, there were fewer Aβ-positive
subjects involved in the study in total (n = 230) after
4 years than at the beginning of the study (n = 749)
(Fig. 2). The number of participants in the CNAβ-positive
(and negative) groups decreased from 115 and (237) at
the beginning of the study to 69 and (143) after 4 years,
respectively, while the number of subjects in the MCI Aβ-
positive (and negative) groups started at 356 and (226),
and declined to 168 and (149) after 4 years. The AD group
has amassive drop from 179 at baseline to only 10 subjects
after 4 years.
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Fig. 3 Graph showing the MMSE score development for CN, MCI, and AD subjects split by Aβ-status. The shaded areas represent 95% confidence
intervals for the mean values. The number of subjects decreases over time, hence the growing uncertainty bands
Task A: Predicting change in MMSE score
In Table 2, we report the performance of the linear regres-
sion and the gradient boosting (GB) models that predict
the change in MMSE scores after 2 and 4 years, respec-
tively, as measured using the average cross-validated R2
score and standard deviation. The standard deviation was
computed across the held-out validation sets correspond-
ing to different cross-validation folds. We compare mod-
els fit using only cognitive test scores measured at baseline
as predictors, to models fit using a preselected feature set
described previously.
The best 2-year MMSE prediction model achieved an
R2 of 0.388 (std. 0.073) using all features and a linear
regression model utilizing all subjects but weighted dur-
ing training. This model scored marginally higher than
restricting the training data to only Aβ subjects with a R2
of 0.372 (std. 0.081). The gradient boosting models per-
formedworse across the three cohort selections compared
with their linear regression counterparts. These results
do not indicate any immediate benefit from using non-
linear estimators to model cognitive score change in this
sample. The best prediction for the 2-year follow-up using
only cognitive tests resulted in an R2 of 0.350 (std. 0.079)
which is only slightly lower than the best model using all
features.
The best cross-validated R2 score for predicting change
in MMSE after 4 years was 0.325 (std. 0.134), using all
features and a linear regression model using the equally
weighted cohort in the training. Using only cognitive tests
for this task gives a lower score indicating that other
biomarkers offer more than in the 2-year case. Using only
the Aβ subjects for this task results in quite poor pre-
dictions with high variability compared to utilizing the
weighted sample cohort or the weighted equally cohort
while training, indicating that more data can significantly
improve the training of these models. Similarly to the
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Table 2 Performance of the linear and gradient boosting
regressions, predicting change in MMSE 2 and 4 years after
baseline for three different cohort selections. We compare
models trained on features a) the all features set from baseline
and b) from baseline cognitive scores only
R2 (SD) 2-year follow-up 4-year follow-up
All features
LR, Aβ only 0.372 (0.081) 0.205 (0.227)
LR, all subjects 0.354 (0.083) 0.325 (0.134)
LR, all subjects, weighted 0.388 (0.073) 0.304 (0.152)
GB, Aβ only 0.287 (0.124) 0.156 (0.244)
GB, all subjects 0.356 (0.108) 0.252 (0.191)
GB, all subjects, weighted 0.338 (0.950) 0.263 (0.192)
Cognitive tests only
LR, Aβ only 0.343 (0.087) 0.178 (0.203)
LR, all subjects 0.333 (0.081) 0.228 (0.143)
LR, all subjects, weighted 0.350 (0.079) 0.225 (0.160)
GB, Aβ only 0.272 (0.133) − 0.050 (0.358)
GB, all subjects 0.323 (0.118) 0.149 (0.224)
GB, all subjects, weighted 0.293 (0.114) 0.118 (0.227)
2-year setting, the gradient boostingmodels showed lower
performance than the linear models.
Across both tasks A1 and A2, linear models using
the larger feature selection and utilizing more subjects
than just the cohort containing only Aβ positive subjects
performed considerably better in predicting the change of
the MMSE score.
Figure 4 shows a calibration plot for held-out data cor-
responding to a single fold from the cross-validation from
a linear regression model predicting MMSE change after
2 years. Calibration was good for smaller declines but
worse for faster-declining subjects, for which the predic-
tions underestimated the change. This trend was consis-
tent across the two follow-up lengths; there are a few
subjects whose change in the MMSE score is significantly
larger than others and therefore are more difficult to pre-
dict. These outliers may potentially also have decreased
the quality of predictions of other data points.
In Table 4 in the supplementary material, we list the
importance measures of features across the 2-year predic-
tion models using all features. For predicting change in
the MMSE score, the most important features were base-
line cognitive scores, with ADAS13, TRABSCORE, and
ADAS11 being the most predictive. The linear models
additionally selected the mPAACCtrailsB, LDELTOTAL
and ADASQ4 while other cognitive tests such as FAQ and
RAVLT_immediate were chosen by the gradient boost-
ing models as part of the most predictive features. This
is expected since subjects with early disease status (e.g.,
with high baseline MMSE score) tend to change less
rapidly than already progressing subjects [57]. For this
reason, we included also the results of estimators predict-
ing change in MMSE based only on baseline cognitive
scores in Table 2. However, we see that across all mod-
els and tasks, the performance improved slightly by using
additional predictors.
Several features were only identified as important by
one or two models across the cohorts. For instance, the
volume measurement of WholeBrain was selected by two
gradient boosting models including all subjects equally
weighted and the Aβ only cohort. Moreover, the FDG fea-
ture, obtained by PET and known to be a strong marker
for AD [47] is selected in the cohort including only Aβ
positives among the five most important features.
The estimated levels of Aβ measured through Aβ42 in
CSF and AV45 PET scans showed low predictive power
in the context of other features across all cohorts and
models. For example, the Aβ42 measurements were only
included with a coefficient of 0.30 in the linear regression
model using all subjects equally weighted and −0.01 when
training with only Aβ subjects and the AV45 is rated even
less predictive.
For the 4-year predictions, the features that are rated
most important in the linear regression models are a
dementia diagnosis, TAU and PTAU proteins in CSF fol-
lowed by the mPACCtrailsB and ADASQ cognitive tests.
The gradient boosting models however deem FDG along
with the cognitive scores ADAS13, FAQ, and mPACC-
trailsB to be of most importance for making predictions.
Comparing to the 2-year predictions, it is interesting to
see the increased value in using biomarkers other than
cognitive tests. The 4-year predictions also indicate low
predictability by Aβ-related features when predicting the
rate of decline in Aβ-positive individuals.
Task B: Predicting diagnosis change
In Table 3, we report the results of predicting a worsened
diagnosis at the 2-year follow-up visit. Gradient boosting
using all features and an equally weighted cohort dur-
ing training resulted in the best performance, achieving
a cross-validated weighted F1 score of 0.791 with a stan-
dard deviation of 0.042. However, the gradient boosting
model with weighted subjects in the cohort reaches only a
slightly lower weighted F1 score of 0.782 with a standard
deviation of 0.040. The logistic regression models consis-
tently perform worse than the gradient boosting ones on
the diagnosis prediction for the 2-year follow-up.
When using only the cognitive tests, the best perform-
ingmodel also uses gradient boosting and a cohort includ-
ing all subjects weighted equally achieving a weighted F1
score of 0.787 with a standard deviation of 0.043. This
is very close to the previous result using all features.
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Fig. 4 A calibration plot (true vs predicted values) for a linear regression model that predicts the change in MMSE score 2 years from baseline
Similarly, the models using only cognitive tests performed
marginally worse than their counterparts using all fea-
tures. In summary, additional features lead to only a slight
improvement in the performance for both logistic regres-
sion and gradient boosting.
The most important features for the diagnosis mod-
els over all three training cohorts are LDELTOTAL and
mPACCtrailsB. This result demonstrates that the two
most important features in progression prediction belong
to the group of cognitive assessment. The logistic regres-
sion models also selected as important: TAU, PTau, two
APOE4 genes, and DX_NUM_1.0 which represents the
MCI diagnosis at baseline. However, the gradient boosting
Table 3 Performance of the classification models in predicting
change in diagnosis 2 years after baseline for three different
cohort selections
Weighted F1 (SD) Follow-up after 2 years
All features Cognitive tests only
LR, Aβ only 0.763 (0.050) 0.761 (0.046)
LR, all subjects 0.781 (0.044) 0.762 (0.050)
LR, all subjects, weighted 0.776 (0.047) 0.770 (0.046)
GB, Aβ only 0.770 (0.043) 0.784 (0.041)
GB, all subjects 0.788 (0.045) 0.793 (0.039)
GB, all subjects, weighted 0.786 (0.046) 0.787 (0.037)
models identified several other cognitive test scores as
important features, for example, FAQ, TRABSCOR, and
ADAS13. Similarly, to the prediction of the change of
MMSE score, one can conclude that the Aβ42 obtained by
CSF as well as the AV45 retrieved by PET are not among
the most important features for any of the diagnosis
change models.
We can conclude that the logistic regression models
and the gradient boosting models rely on similar features.
There are bigger differences between important features
in logistic regression models than those using gradient
boosting.
Relating predicted cognitive decline & diagnosis change
In Fig. 5, we plot the predictions made by models for
tasks A1 and B for the same set of baseline-MCI subjects.
Overall, we see a strong correlation between predicted
cognitive decline (negative change in MMSE) and pre-
dicted change from MCI to AD status. The variance in
predicted MMSE change is larger for AD-transitioning
subjects than for MCI-stable subjects.
Discussion
Formation of amyloid-beta plaques in the brain is a hall-
mark of Alzheimer’s disease. Only recently, the first drug
which may mitigate or slow down the formation of these
plaques was approved by the FDA [58, 59]. To best
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Fig. 5 Predicted change in MMSE score and the predicted probability of a change in diagnosis after 2 years in the baseline-MCI group. Points are
color-labeled based on their observed change in diagnosis
target future interventions of this kind, it is of great inter-
est to identify individuals who are most likely to suffer
rapid cognitive decline. Since presence of Aβ plaques is
required for an AD diagnosis and can be detected early in
CSF and plasma, successful prediction of who among Aβ-
positive subjects are likely to deteriorate first could have
significant clinical implications.
Machine learning approaches, including classification
[23, 24] and regression [26, 28] methods, have been used
to predict progression of patients from CN to MCI and
from MCI to AD. The results show that subjects who
already have cognitively declined are most likely to dete-
riorate more rapidly. However, although such studies have
shown that Aβ levels among others are strong predictors
of the transition fromMCI to an AD diagnosis [13, 20, 27],
prediction of progression specifically for patients with
established amyloid pathology is so far unexplored.
In this work, we studied prediction of cognitive
decline in an Aβ-positive cohort using machine learning
methods. We applied multivariate statistical analyses to
explain the variation in changes in cognitive scores and
diagnoses, between subjects in the ADNI dataset, as a
function of commonly available clinical variables. We
found that the predictability of changes in cognitive
test scores was low, leaving a large portion of variance
unexplained. Our results complement previous works
which show good discrimination of progressing and non-
progressing subjects [16, 21] in cohorts comprising both
Aβ-positive and Aβ-negative subjects. In particular, we
show that discriminating between subjects who are poten-
tial candidates for drugs designed to reverse or slow down
Aβ plaque formation presents a harder prediction task.
Predictors of progression in amyloid-positive subjects
Confirming previous results, we found that the ratio of
Aβ42 and Aβ40 CSF level is a good first-line predictor
of decline in the MMSE score [43]. However, when lim-
iting the cohort to only the Aβ-positive subjects, the
predictive power of the levels of Aβ42 and Aβ40 was sub-
stantially reduced. In other words, the Aβ biomarkers
served predominantly to produce a binary grouping of
subjects.
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The most important features for predicting disease pro-
gression in all considered tasks were baseline cognitive
test scores. Although related work has not focused specif-
ically on the Aβ-positive cohort, these results are consis-
tent with previous results in selecting cognitive tests such
as the MMSE and ADAS13 tests as important predictive
features [29, 44]. Our analysis demonstrated that cognitive
test results indicate well how the individual will progress
and that those who were already cognitively impaired
would likely deteriorate more. Since most of the cognitive
test scores are highly correlated, several cognitive scores
could perhaps be combined and summarized in a joint
variable rather than using all of them separately. Apart
from cognitive scores, some of the CSF biomarkers, brain
scans and other biomarkers showed lower average impor-
tance as predictors for progression when including all
subjects. This can partially be explained due to the higher
missingness of these features when viewing all subjects.
Increasing training cohort
Increasing the number of subjects by adding those that
were not in the Aβ-positive cohort to the training set con-
sistently increased the predictions performance for that
group. Therefore, it seems the Aβ-negative subjects have
fairly similar characteristics that determine their cogni-
tive decline. A weighting procedure allowing us to include
more subjects in the training gave a better performance
than using only the subjects we were interested in pre-
dicting. The increased performance from the addition of
out-of-cohort samples also indicates that more data would
increase the quality of the prediction tasks even further.
In the case of predicting MMSE change after 4 years,
using a small cohort of only Aβ-positive subjects gave a
drastically worse performance.
MMSE as target variable
The MMSE score has been used frequently in demen-
tia research for grading the cognitive state of patients
[60, 61]. For this reason, the change in MMSE score was
used in this work as a target variable and thus as a proxy
for a person’s cognitive change. The test benefits from
high practicability as the typical administration time is
only 8 min for cognitively unimpaired individuals and
increases to 15 min for individuals with dementia. Inter-
nal consistency appears to be moderate and test-retest
reliability good [62].
The MMSE is neither the most accurate nor the most
efficient instrument for assessing cognitive impairment,
nor is it designed specifically for AD. Despite its frequent
use, theMMSE lacks sensitivity in patients with high levels
of premorbid education and suspected early impairment
[63]. Especially for studies that screen cognitively nor-
mal populations for evidence of cognitive impairment,
the Montreal Cognitive Assessment (MOCA) may be
better able to detect age-related cognitive decline in adults
since it eliminates the ceiling effects of MMSE [64]. The
ADAS13 cognitive test which we used in the primi-
tive studies could also function as a target variable. The
ADAS13 test is also commonly used in clinical trials to
thoroughly identify incremental improvements or deteri-
orations in cognitive performance. Although the ADAS is
genuinely accurate in distinguishing individuals with nor-
mal cognition from those with impaired cognition, some
research studies indicate that the ADAS test may not be
difficult enough to consistently detect only mild cognitive
impairment [33, 65, 66]. Alternatively, for future work, the
outcome variable could be a combination of several cogni-
tive tests, which outweighs the individual characteristics
of a single cognitive test.
Clinical implications
Prediction of cognitive decline among Aβ-positive sub-
jects could have clinical implications in a scenario where
a disease-modifying drug becomes available on the mar-
ket. In this case, our approach could be used to assess
how an Aβ-positive person, either unimpaired or already
in cognitive decline, might develop in the near future.
With a further developed predictive approach, physi-
cians could be supported in the prioritization and eval-
uation of patients for treatment. In particular, models
with interpretability aspects may encourage clinicians to
use machine learning-based decision-making methods in
a clinical context. Further, our approach benefits from
relying only on a small number of biomarkers and demo-
graphic data that are widely available for many patients
and therefore provides high practical relevance. In order
to be able to generalize results even better, more accessible
patient data will be needed in the future. For an efficient,
timely, and practical approach to predicting disease devel-
opment in Alzheimer’s patients, the approach of precision
medicine could be important. With the goal of improving
the health of well-defined patient populations, precision
medicine will affect all stakeholders in the healthcare sys-
tem at multiple levels, from the individual perspective to
the societal perspective [67].
Limitations
Our study should be viewed in light of the following lim-
itations. First, there was significant missingness in the
target outcome variables, MMSE and diagnosis status, for
all prediction tasks. Since these are the targets of predic-
tion, they were not imputed and only subjects with the
available output variables were included. Consequently,
the cohorts for tasks A1, A2, and B were all different and
potentially biased subsets of the initial cohort. For exam-
ple, the cohort sizes for the regression tasks differ based
on whether the MMSE test score variable was available
after 2 years (A1, n = 500) or after 4 years (A2, n = 230).
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The missingness of outcome variables at follow-up time
is partly explained by subjects leaving the study before
follow-up. The reason for subjects to end their partici-
pation in the study is not known but may be related to
disease progression [68]. This phenomenon can bias the
trend of the Aβ positive subjects decreasing their MMSE
score (Fig. 3). However, the dropout rate of people was
around 40% in both CN groups and the MCI Aβ-negative
one while there wasmore dropout in theMCI Aβ-positive
group where it was 55% and a staggering 94% for the AD
group. Consequently, if more people with lower cognitive
function would have been included, the average MMSE
score would be lower, and therefore, the slope of the graph
would be slightly steeper and result in an even lower
average MMSE score.
As a consequence of the prohibitively small and imbal-
anced cohorts, we performed a grouped analysis. The use
of non-Aβ-positive subjects in deriving progression pre-
diction models reduces variance by increasing the sample
size of cohorts that had small numbers of subjects. How-
ever, this risks bias in terms of the best model for Aβ-
positive subjects. Note that Aβ-positive-negative subjects
were used in the derivation of predictive models, but not
in evaluation.
Conclusions
We studied the problem of predicting disease progres-
sion and cognitive decline of potential AD patients with
established Aβ pathology in the ADNI database. The best
performing model achieved a performance of R2 = 0.388
predicting the change in MMSE scores 2 years after base-
line using a linear regressionmodel based on a cohort with
weighted samples in the training cohort using all features
at baseline. Similarly, a gradient boosting model with all
subjects weighted equally predicted the change in diag-
nosis with high accuracy (F1 = 0.791) when using all
features. For the most accurate predictions, our models
combine variables measured at the baseline such as cogni-
tive tests, CSF biomarkers, proteins and genetic markers.
Among these, baseline cognitive tests scores were found
to be the strongest predictors, accounting for most of the
variance explained by all features, across models. Finally,
we identified that even though the Aβ42/Aβ40 ratio is a
good predictor for AD in the preclinical phase, the respec-
tive levels of Aβ are less useful in predicting progression
among only Aβ-positive subjects.
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